The study, presented at the American Society of Hematology meeting, also suggested that a moleculary guided strategy may lead to better outcomes than standard of care.
Amgen's latest deal with a pharma company will see its clonoSeq assay used for minimal residual disease testing in a clinical trial for venetoclax.
An analysis found a 14 percent prevalence of germline cancer risk mutations and a 57 percent prevalence of variants of unknown significance.
The companies had agreed in early 2018 to collaborate on the development of technologies to support precision oncology initiatives, but Roche said "priorities" have changed.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The researchers profiled 44 cancer-related genes in 191 individuals with familial breast cancer, colorectal cancer, or other forms of early-onset cancer.
Using systems biology, investigators put cancer risk SNPs in a network context, identifying immune, tumor-related, and other genes influenced by the variants in multiple tissue types.
The researchers believe their findings could be used to change how patients' risk for breast cancer, colon cancer, or heart disease is calculated.
These alterations, which can include hypermethylation of the H19 locus, can crop up during kidney development.
While NanoString will commercialize its nCounter for research use applications, Veracyte will move its current assays onto the platform to reach a global audience.
The guidelines place a stronger emphasis on pancreatic cancer risk genes, and broaden testing recommendations for those with Ashkenazi Jewish ancestry.
The company is using the test to direct patient enrollment and treatment stratification in a trial of pembrolizumab (Keytruda) combination treatments.
The FDA approved FoundationOne CDx as a companion diagnostic for alpelisib in combination with fulvestrant to treat certain PIK3CA-mutated breast cancers.
The firms are combining Caris' somatic and Ambry's germline testing to provide clinicians with information on patients' cancers.
The Dutch companies will use sequencing- and machine learning-based methods to quantify genomic instability-causing mutations in blood cells.
Veracyte has also acquired Nanostring's Prosigna breast cancer and LymphMark lymphoma assays and plans to develop diagnostic tests using the nCounter platform.
ArcherDx will develop in vitro diagnostic tests, including companion diagnostics, to run on Illumina's NextSeq 550Dx next-generation sequencing system.
The platform matches a patient's medical history and other data with national guidelines to recommended medically actionable genetic tests.
CUTseq uses enzyme-based fragmentation and in vitro transcription to barcode DNA, saving money when preparing 1,000 samples or more.
Researchers compared single-cell transcriptomic and epigenetic profiles of healthy blood cells and leukemia samples to find a role for RUNX1 in disease.
Researchers have sequenced the genome of the depth-dwelling giant squid.
Prosecutors have charged a former Drexel University professor with theft for allegedly spending federal grant money on adult entertainment and other unrelated expenses, according to the Philadelphia Inquirer.
Chris Collins, a former US representative, has been sentenced to more than two years in prison in an insider trading case involving an Australian biotechnology firm, the New York Times reports.
In PNAS this week: Trypanosoma brucei transcripts, estimate of people at risk of inherited retinal disease, and more.